---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-22-000036"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2022-07-14T23:59:59+00:00"
generated_at: "2026-06-24T15:17:34.620331+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics preannounces Q2 rev ~$114.5M (-1% YoY), hires Jim Wilbur as CCO

## Summary
- Preliminary Q2 rev of ~$114.5M, down ~1% YoY from $115.8M and flat sequentially.
- Americas rev grew 8% YoY to $70.9M; EMEA fell 11% to $25.6M; APAC fell 15% to $18.1M.
- CEO says results 'fell short of our expectations'; full Q2 results and FY2022 guidance on Aug 8.
- Appointed Jim Wilbur, Ph.D., as Chief Commercial Officer effective July 27; outgoing CCO Brad Crutchfield to transition through Dec 2022.

## SEC filing metadata
- accession: 0001770787-22-000036
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2022-07-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000036/0001770787-22-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000036/txg-20220712.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-22-000036
- JSON: https://secwatch.observer/filing/0001770787-22-000036.json
- Plain text: https://secwatch.observer/filing/0001770787-22-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.